NCT03545035 (LLC178) is a clinical trial of idelalisib and rituximab in Chronic Lymphocytic Leukemia, sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto.

Who is sponsoring NCT03545035?

NCT03545035 is sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto.

What drugs are being tested in NCT03545035?

Interventions in NCT03545035: idelalisib and rituximab.

What condition does NCT03545035 study?

NCT03545035 studies Chronic Lymphocytic Leukemia.

Is NCT03545035 still recruiting?

NCT03545035 is currently completed. Last updated 12 May 2022.

Last reviewed 2022-05-12 · How we verify

NCT03545035: LLC178

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study

Completed Last updated 12 May 2022

What this trial tests

trial testing idelalisib and rituximab in Chronic Lymphocytic Leukemia in 104 participants. Completed in 28 October 2020.

Timeline

6 February 2019

Primary endpoint
28 October 2020

28 October 2020

Quick facts

Lead sponsor	Gruppo Italiano Malattie EMatologiche dell'Adulto
Status	Completed
Study type	OBSERVATIONAL
Enrollment	104
Start date	6 February 2019
Primary completion	28 October 2020
Estimated completion	28 October 2020
Sites	38 locations across Italy

Drugs / interventions tested

idelalisib and rituximab — full drug profile →

Conditions studied

Chronic Lymphocytic Leukemia — all drugs for Chronic Lymphocytic Leukemia →

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto — full company profile →

Who can join

18 and older, any sex, with Chronic Lymphocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study aims at obtaining more in-depth information on how patients with chronic lymphocytic leukemia treated with idelalisib and rituximab react to treatment.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J, Nie J, Ma X, Wei Y, et al · · 2019 · cited 1142× · PMID 30782187 · DOI 10.1186/s12943-019-0954-x
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.
Jiang N, Dai Q, Su X, Fu J, et al · · 2020 · cited 419× · PMID 32333246 · DOI 10.1007/s11033-020-05435-1
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.
Rigolin GM, Cavazzini F, Piciocchi A, Arena V, et al · · 2021 · cited 9× · PMID 33739461 · DOI 10.1002/hon.2861
The importance of <i>TP53</i> status in cancer therapy: The example of chronic lymphocytic leukemia.
Mirgayazova R, Khadiullina R, Gilyazova E, Davletshin D, et al · · 2025 · cited 1× · PMID 40321704 · DOI 10.22099/mbrc.2025.51477.2054

Verify or expand the search:

Other recruiting trials for Chronic Lymphocytic Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal · Phase 2 · recruiting
NCT07288515 — Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus · recruiting
NCT07014917 — Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL · Phase 2 · recruiting

Other Gruppo Italiano Malattie EMatologiche dell'Adulto trials

Trials by the same sponsor.

NCT07356960 — Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world · not yet recruiting
NCT07158294 — Identification of BCR::ABL1 Mutations by Digital PCR in CML · NA · not yet recruiting
NCT07249606 — Momelotinib Effectiveness in Myelofibrosis · not yet recruiting
NCT06880601 — Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma · Phase 2 · not yet recruiting
NCT06657846 — HRQoL and Financial Toxicity in Patients With VEXAS Syndrome · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03545035 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gruppo Italiano Malattie EMatologiche dell'Adulto
Last refreshed: 12 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03545035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing